Loading market dashboard
Pfizer Inc.
PFEHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Pfizer's net income is under pressure, and likely will be for the foreseeable future. Although its replenished pipeline and portfolio should help, Pfizer paid a sizable price for this growth.
Pfizer is a highly respected pharmaceutical company. The drug maker is dealing with a mismatch between its new drug development and patent expirations.
Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of Metsera last year had a similar side-effect profile as rival Novo Nordisk's weekly injection Wegovy.
Have you ever heard of Succession Risk? It occurs when key leaders of a company leave their position—whether expected or not—and a clear successor isn't already in place.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF'3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA). The objectives for the Phase 2 studies were to identify the right doses for Phase 3 and to test escalation schemes. Across both weekly and monthl.
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.2%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the company engineering AI models to discover new molecules, announces a license agreement with Pfizer.
L
Durability, not yield, is the deciding factor.
Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
PepsiCo, AT&T, and Pfizer are blue chip dividend stocks that offer high yields. Their valuations are incredibly modest when compared to the average S&P 500 stock.
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly.
Both are working hard to get around patent cliffs. One of them seems to have made more progress on that front.
This biotech is making solid progress with several pipeline candidates. It could have a stronger lineup of approved products within a few years.
You should consider these strategies if you can't afford to wait out another market crash.
PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.
Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple.
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
These aren't the most exciting businesses, but they have a lot to offer to long-term investors.
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:00 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcri.
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Office
Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.
Pfizer's stock has fallen more than 50% from its 2021 high. The stock is trading below its pre-coronavirus pandemic level.
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B
Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These results will be.
Pfizer is dealing with what are really just normal headwinds for a drug company. Although the near term is likely to be challenging, a material stock sell-off appears to have priced in the bad news.
Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNAÂ (talazoparib), an oral poly ADP-ri
NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC). At seven years, patients treated with LORBRENA had a 55% likelihood of re.
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but retain rights in the Greater China market.
Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 early-stage cancer medicines, the companies said on Friday.
NEW YORK & SAN FRANCISCO & SUZHOU, China--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with nove.
SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs.
The smart money on Pfizer (NYSE: PFE | PFE Price Prediction) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size in either direction, and the dividend yield is doing the heavy lifting.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 2:00 p.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning to.
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executi
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
Astellas Pharma (ALPMY) is trying to give investors a new growth story as Xtandi, its blockbuster prostate cancer drug co-marketed with Pfizer (PFE), moves clos
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking's VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not... If Viking Therapeutics Is Acquired, Here's Who Wins
Pfizer is offering investors a huge 6.6% dividend yield. The pharmaceutical giant isn't hitting on all cylinders, but dividend investors shouldn't abandon the company yet.
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
The Dividend Harvesting Portfolio reached a record $39,166.48, up 43.47% on invested capital, with forward annualized dividend income surpassing $3,000. My disciplined, diversified approach—capping positions at 5% and sectors at 20%—enables risk mitigation and robust, recurring income growth. Recent additions include AGNC (13.4% yield, strong dividend coverage) and Pfizer (6.5% yield, reaffirmed bullish 2026 guidance), positioning for a potential lower-rate environment.
As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.
Pfizer's dividend yield is far higher than AbbVie's, but the key issue is whether the payout is safe. AbbVie has been a dividend growth beast for several years, and that trend could very well continue.
Investors tend to jump from one hot investment idea to another. Right now, GLP-1 drugs are the hot story, and this pharmaceutical giant isn't even in the game yet.
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PFE's aggressive M&A and in-house R&D efforts are paying off, with the growth portfolio (newly launched/acquired products) already delivering $3.1B in revenues in FQ1'26 (+22% YoY operationally). LOE risks are mitigated by delayed Vyndamax generic entry to mid-2031, supporting the management's high single-digit 5Y revenue growth guidance from 2029 onwards. PFE's intermediate-term performance is expected to remain lumpy, but the cost saving efforts, strong interest coverage, and dividend sustainability underpin its compelling investment thesis.
Pfizer (PFE) is trying to defend one of its most important vaccine franchises with a next-generation version of Prevnar, after early trial data suggested the ex
Johnson & Johnson offers a superior return/risk profile versus Pfizer, driven by consistency and operational stability. PFE's far lower valuation (FWD P/E 8.55x, PEGY 0.97x) and far higher yield (6.79%) are certainly attractive. But JNJ's 63-year streak of dividend growth, lower payout ratio (48.46%), ongoing buybacks, and stable inventory all point to far superior consistency.
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer's oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home. Central to the collaboration is SCRI's Accelero™, a next-generation clinic.
Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up to 15-fold higher antibody levels against a key strain, in a mid-stage study.
